Hepatocellular carcinoma (HCC) is the most common liver cancer and is highly malignant. Current diagnostic tests are blood, imaging and biopsy, with no useful predictive biomarker. Additionally, targeted therapies are unavailable, which hinders the potential for personalized therapy in HCC patients. Here, we discuss the limited studies conducted thus far to identify molecular targets for early detection and treatment of HCC, their limitations and future directions in this field. However, the integration of multi-omics analyses, such as genomics, proteomics, and phosphoproteomics, has provided valuable insights into the mechanisms and pathways underlying the disease.
Objective: To identify and compare current modifiable and non-modifiable risk factors for pancreatic cancer (PaCa) that may have potential application in PaCa risk stratification, prevention, and early detection. Material: All articles in this literature review were identified through systematic searches of PubMed, Medline
Understanding the currently available evidence regarding multimodal approaches is critically important.The Southwest Oncology Group INT-0116 trial demonstrated improved overall survival and disease-free survival using adjuvant therapy-specifically CRT-compared to surgery alone [16].Subsequently, several other studies have supported the use of postoperative chemotherapy and/or CRT in addition to surgery with improved outcomes [17][18][19][20][21].This was followed by the MAGIC trial, which demonstrated a survival advantage for the use of perioperative combination chemotherapy (epirubicin, cisplatin,) as compared to resection alone and
